News IRLAB Therapeutics AB

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm 12:00:00 2026-11-06 EST			5-day change	1st Jan Change
2.050 ^SEK	+2.60%		-1.91%	+4.06%

10-27	Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate	MT
10-27	Irlab receives positive patent notice in the US for IRL1117	FW

All News

Mentions Relevance

10-27	Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate	MT
10-27	Irlab receives positive patent notice in the US for IRL1117	FW
10-20	Irlab research behind linepemat published in journal	FW
10-20	IRLAB Therapeutics AB Announces Publication Of Preclinical Research Underpinning Linepemat In Peer-Reviewed Journal	CI
10-09	IRLAB to present at Redeye Theme: Neurology	AQ
09-24	Irlab appoints Janne Backman as new chairman	FW
09-24	IRLAB Appoints Janne Backman as New Chairman of the Board	AQ
09-24	Irlab Therapeutics AB Announces Board Changes, Effective September 25, 2026	CI
09-03	IRLAB's CEO Intends to Step Down During the First Quarter of 2027	AQ
09-03	Irlab CEO Kristina Torfgaard to step down in 2027	FW
09-03	Irlab CEO Kristina Torfgaard wants to step down	FW
09-03	Irlabs CEO to step down in Q1 2027	FW
09-03	IRLAB’s CEO intends to step down during the first quarter of 2027	AQ
09-03	IRLAB Therapeutics AB Announces Resignation of Kristina Torfgård from CEO Role	CI
08-31	New number of shares and votes in IRLAB Therapeutics AB	AQ
08-28	Redeye sets a justified value of 6.60 kronor for Irlab, partnerships remain in focus	FW
08-26	IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-26	Irlab cuts revenue and operating loss	FW
08-26	IRLAB publishes interim report for the period January - June 2026	AQ
08-20	IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast	AQ
08-19	IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO	AQ
08-19	Irlab's IRL757 is assigned the name linepemat by WHO	FW
08-19	IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO	AQ
08-19	IRLAB Therapeutics AB's Drug Candidate IRL757 Receives Generic Name Linepemat From WHO And Provides Update On Clinical Development	CI
07-31	New number of shares and votes in IRLAB Therapeutics AB	AQ